MBK-01, orally administered biologic medicine based in primary or recurrent Clostridiodes difficile infection

During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost discussed with Juan Basterra, CEO at Mikrobiomik, about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.